Plasma proteomic analysis of presymptomatic individuals with amyotrophic lateral sclerosis identifies novel disease-associated proteins and enables the development of an accurate diagnostic biomarker ...

With this treatment schedule, IL-2LD resulted in a non-significant reduction in mortality in the primary unadjusted analysis. However, the difference between the results of unadjusted and adjusted ana...

A new study has explored how toxic proteins build up in the nervous system and whether future treatments might help stop them.

The child, who is now almost three years old, shows no signs of the often fatal motor neuron disease.

As neurologists specialising in the care of people living with motor neuron disease, we are receiving increasing enquiries about a drug called ellorarxine. Many of our patients are asking for access, ...

Blood level of neurofilament light chain as a biomarker for neurological disorders

EXPERTS-ALS is a ground-breaking initiative to accelerate the development of new treatments for amyotrophic lateral sclerosis (ALS). We’re excited to showcase one of our flagship projects, the EXPErim...

Get access to 'Countdown to a cure' which provides an overview of the innovative research the MND Association is funding, the increased collaboration across MND research, and a look at new and improve...

There is a long history of ALS therapies being promoted on the basis of Phase 2 data, which then fail to translate into meaningful benefits in Phase 3 tria

Dr. Alfredo Iacoangeli has been awarded the prestigious Paulo Gontijo Award, recognising his vital contributions to MND research. We are delighted to announce that Dr Alfredo Iacoangeli was awarded t...

UK MND Research Institute: Updates for late 2024 As we move towards the end of 2024, having recently marked the 1st anniversary of the formal launch of the UK MND Research Institute, we bring you 4…

Over 15,000 people signed the charity’s petition.